Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 16/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olpadronic Acid SCHEMBL6439356 | 0.87 | FDPS (0.54) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL2178802 | 0.87 | FDPS (0.63) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL6669236 | 0.84 | FDPS (0.63) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL18898 | 0.80 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL6270347 | 0.80 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL8050464 | 0.80 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL17499972 | 0.79 | FDPS (0.54) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL19614558 | 0.78 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646147 | 0.78 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579001 | 0.78 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023090899-A1 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | (주)인벤티지랩 | 2023-05-25 | — | — | WO | claimed |
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240200146-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240190967-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240175088-A1 | Methods and Systems for Analyzing Nucleic Acid Molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240158513-A1 | FC Variants and Methods for Their Production | GENENTECH, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC | 2024-05-09 | — | — | US | disclosed |
| US-11965215-B2 | Methods and systems for analyzing nucleic acid molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4334476-A1 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20040043072-A1 | Alleviation of upper gastrointestinal irritation | WILL JOANNE PATRICIA (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1378234-A1 | Effervescent bisphosphonate formulation | MERCK & CO. INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-0939624-B1 | EFFERVESCENT BISPHOSPHONATE FORMULATION | MERCK & CO INC (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1311213-A1 | VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030003147-A1 | Effer-vescent bisphosphonate formulation | MERCK & CO., INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002009631-A1 | VAGINAL DELIVERY OF BISPHOSPHONATES | UMD, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010041165-A1 | Effervescent bisphosphonate formulation | MERCK & CO., INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1102590-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LTD. (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007598-A1 | USE OF A NK-1 RECEPTOR ANTAGONIST FOR TREATING OR PREVENTING ABNORMAL BONE RESORPTION | MERCK SHARP & DOHME LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
| US-5853759-A | Effervescent alendronate formulation | MERCK & CO.. INC. (US) | 1998-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148760-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | CNR2, CNR1, FAAH | FDPS 1169/4885PDE3A 2026/4885LMNA 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.